文献速递哮喘

哮喘患者的超额医疗费用及合并症的作用

Excess medical costs in patients with asthma and the role of comorbidity.
PubMed 文献 · Eur Respir J · 2016-10-06

该研究基于加拿大不列颠哥伦比亚省1997-2012年健康行政数据,构建倾向评分匹配队列,比较5-55岁新诊断哮喘患者与非哮喘对照者的直接医疗费用。结果显示平均总体超额费用为每人年1058加元(95%CI 1006-1110),其中哮喘归因134加元,主要合并症类别归因689加元。精神疾病是超额合并症费用的最大组成部分,合并症归因超额费用随年龄大幅增加但不随哮喘病程延长而增加。

要点

  • 哮喘患者平均总体超额直接医疗费用为每人年1058加元,其中哮喘本身仅占134加元。
  • 主要合并症类别贡献689加元的超额费用,精神疾病是最大组成,其次为消化系统、神经系统和非哮喘呼吸系统疾病。
  • 合并症归因超额费用随年龄大幅增加,但不随哮喘病程延长而增加。

核心结论

  • 哮喘患者超额医疗费用中合并症贡献远大于哮喘本身,制定哮喘管理政策和指南时应同时考虑哮喘及合并症相关结局。

研究设计与样本

  • 基于加拿大不列颠哥伦比亚省1997-2012年健康行政数据,构建倾向评分匹配队列,纳入5-55岁新诊断哮喘患者与非哮喘对照者。

主要发现

  • 平均总体超额费用为每人年1058加元(95%CI 1006-1110)。
  • 其中哮喘归因超额费用为134加元(95%CI 132-136),主要合并症类别归因689加元(95%CI 649-730)。
  • 精神疾病是超额合并症费用的最大组成部分,其次为消化系统疾病、神经系统疾病和非哮喘呼吸系统疾病。
  • 合并症归因超额费用随年龄大幅增加,但不随哮喘病程延长而增加。

临床怎么用

  • 评估哮喘经济负担和管理策略时,应重视合并症的识别与处理,尤其是精神疾病、消化系统疾病和神经系统疾病。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Asthmatic patients frequently have comorbidities, but the role of comorbidities in the economic burden of asthma is unclear. We examined the excess direct medical costs, including asthma- and comorbidity-related costs, in patients with asthma.We created a propensity score-matched cohort of patients newly diagnosed with asthma and non-asthmatic comparison subjects, both aged 5-55 years, from health administrative data (1997-2012) in British Columbia, Canada. Health services use records were categorised into 16 major disease categories based on International Classification of Diseases codes. Excess costs (in 2013 Canadian dollars ($)) were estimated as the adjusted difference in direct medical costs between the two groups.Average overall excess costs were estimated at $1058/person-year (95% CI 1006-1110), of which $134 (95% CI 132-136) was attributable to asthma and $689 (95% CI 649-730) to major comorbidity classes. Psychiatric disorders were the largest component of excess comorbidity costs, followed by digestive disorders, diseases of the nervous system, and respiratory diseases other than asthma. Comorbidity-attributable excess costs greatly increased with age but did not increase over the time course of asthma.These findings suggest that both asthma and comorbidity-related outcomes should be considered in formulating evidence-based policies and guidelines for asthma management.

来源:Eur Respir J,查看原文。版权归原作者所有。

引用

  1. Chen W, Lynd LD, FitzGerald JM, et al. Excess medical costs in patients with asthma and the role of comorbidity. Eur Respir J. 2016. PMID: 27824603. doi:10.1183/13993003.01141-2016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。